ZEB2P1

Across TCGA pan-cancer cohorts, ZEB2P1 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ZEB2P1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ZEB2P1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZEB2P1 is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

LIHC, KICH, and BRCA are the cancer types where ZEB2P1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZEB2P1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	All	+0.229	<.001	5	view →
KICH	All	All	−0.111	.001	5	view →
BRCA	Female	All	+0.097	.002	4	view →
THCA	Female	All	−0.079	<.001	4	view →
PRAD	All	All	+0.185	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ZEB2P1–LIHC

Open the LIHC breakdown →